Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01251315 · ClinicalTrials.gov registry record · Phase 1
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels
A Phase 1 study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01251315 is a Phase 1 study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 24 participants.
The verdict
NCT01251315, a Phase 1 study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Glutathione is a powerful protective substance found within every cell in the body. It has been shown that glutathione levels go down as a person gets older, which makes a person more likely to get heart disease, high blood sugar problems and different kind of cancers. N-Acetyl Cysteine is used as a dietary supplement. It has been reported to increase glutathione levels in the body. The diet supplement called ProImmune is also changed by the body into glutathione. Therefore, the purpose of this study is to find out the effect of ProImmune in healthy people. This study will also help to prove whether or not the ProImmune is able to improve the blood levels of glutathione in healthy people.
Interventions
- DRUG Placebo low dose
- DRUG N Acetyl cysteine, 600mg (low dose)
- DRUG Proimmune 200 (FT061452) 3000mg low dose
- DRUG Placebo (high dose)
- DRUG N Acetyl cysteine, 1200mg (high dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01251315
The ClinicalTrials.gov registry entry for NCT01251315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo low dose is the first listed.
NCT01251315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01251315 about?
NCT01251315 is a clinical study titled "The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels". Glutathione is a powerful protective substance found within every cell in the body. It has been shown that glutathione levels go down as a person gets older, which makes a person more likely to get heart disease, high blood sugar problems and different kind of cancers. N-Acetyl Cysteine is used as a...
What is the current status of trial NCT01251315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01251315?
The interventions under investigation include: Placebo low dose (DRUG), N Acetyl cysteine, 600mg (low dose) (DRUG), Proimmune 200 (FT061452) 3000mg low dose (DRUG), Placebo (high dose) (DRUG), N Acetyl cysteine, 1200mg (high dose) (DRUG).
Who is sponsoring clinical trial NCT01251315?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.